Ethical testing stance Strengthen outreach highlighting Epithelix’s focus on reducing animal testing through human tissue models for respiratory diseases and inhalation toxicity, aligning with clients seeking compliant, humane research solutions.

Respiratory disease focus Position offerings as enabling faster, more accurate early-stage testing for asthma, COPD, cystic fibrosis and related respiratory conditions, targeting pharma, biotech, and cosmetics clients with inhalation toxicity needs.

Low revenue growth Acknowledge modest revenue (<$1M) and lean headcount; target partnerships and contract research opportunities with larger CROs or pharma players to scale revenue through service-based collaborations.

Strategic partnerships Leverage PETA alliance and Science Consortium relationships as credibility signals; pursue co-development or licensing deals with organizations seeking validated human tissue models for regulatory submissions.

Global positioning Emphasize Swiss biotech credibility and niche specialization in tissue-engineered human respiratory models to win clients in regulated markets across pharma, cosmetics, and chemical safety sectors seeking non-animal testing solutions.